Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

On February 17, 2026, Casdin Capital disclosed a buy of 1,662,193 shares of Relay Therapeutics (NASDAQ:RLAY), an estimated $11.86 million trade based on quarterly average pricing, in its Form 13F filing. What happened According to an SEC filing dated February 17, 2026, Casdin Capital increased its holding in Relay Therapeutics by 1,662,193 shares, bringing its total to 13,003,574 shares. The estimated transaction value was $11.86 million, calculated using the quarterly average share price. The quarter-en ...